Supplementary Tables – Real-world treatment patterns and overall survival in BRAF-mutant melanoma patients treated with immunotherapy or targeted therapy

Sensitivity analysis 1: Statistical adjustment without inverse probability of treatment weighting (IPTW) Sensitivity analysis 2: Censoring patients in the practice subanalysis who initiate a therapy off-sequence Sensitivity analysis 3: Restricting to CPI patients receiving ipilimumab + nivolumab Supplemental Table 1. Comparison of statistical adjustments with and without inverse probability of treatment weighting (IPTW). Supplemental Table 2. Baseline Characteristics of Patients With Advanced BRAF-Mt Melanoma by 1L Treatment